m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG03191)
| Name |
Cabazitaxel
|
||||
|---|---|---|---|---|---|
| Synonyms |
Cabazitaxel (Jevtana); Cabazitaxel (USAN/INN); Cabazitaxel Injection; Cabazitaxel [USAN:INN]; Cabazitaxelum; Jevanta; Jevtana; Jevtana (TN); Jevtana Kit; RPR 116258A; RPR-116258A; SCHEMBL179674; TXD 258; TXD-258; TXD258; Taxoid XRP6258; XRP 6258; XRP-6258; CABAZITAXEL; Xrp6258; ZINC85536932; cabazitaxel-jevtana; 183133-96-2; 51F690397J; ABP001072; AKOS032947285; AN-1492; BMQGVNUXMIRLCK-OAGWZNDDSA-N; C45H57NO14; CHEBI:63584; CHEMBL1201748; CS-0972; DTXSID40171389; EX-A838; GTPL6798; MFCD18827611; NSC761432; UNII-51F690397J; s3022
Click to Show/Hide
|
||||
| Status |
Approved
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C45H57NO14
|
||||
| InChI |
1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
|
||||
| InChIKey |
BMQGVNUXMIRLCK-OAGWZNDDSA-N
|
||||
| PubChem CID | |||||
| INTEDE Drug ID | |||||
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cytochrome P450 2C8 (CYP2C8)
Fat mass and obesity-associated protein (FTO)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cabazitaxel. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Cabazitaxel through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [1], [2] | ||
Methyltransferase-like 14 (METTL14)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cabazitaxel. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cabazitaxel through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [1], [2] | ||
Methyltransferase-like 3 (METTL3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cabazitaxel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cabazitaxel through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [1], [2] | ||
YTH domain-containing protein 2 (YTHDC2)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cabazitaxel. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Cabazitaxel through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [1], [2] | ||